Drug Trial Radar · NCT04276233
Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
Last checked: Nov 20, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jun 29, 2021
Primary completion
Oct 28, 2023
Study completion Oct 28, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Tech Observer
- First posted
- Feb 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Mepolizumab is a humanized monoclonal antibody (IgG1, kappa) that blocks interleukin- 5 (IL-5) thus inhibits production and survival of eosinophils. The aim of this phase 4, open-label, single-arm study is to evaluate the safety and efficacy of Mepolizumab 100 mg SC administered every 4 weeks in Indian participants aged 18 years or above with severe eosinophilic asthma. After the first dose of mepolizumab, participants will receive 5 more doses of mepolizumab at 4 weekly intervals. Following the last dose of mepolizumab, the end of the study Visit will occur 4 weeks later. During the treatment period, OCS use and dose adjustment in participants will be as per the investigator's discretion and clinical practice.
Conditions
- Asthma
Interventions
MepolizumabDrug
Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.
SalbutamolDrug
Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)Time frame: Up to Week 24
- Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: Up to Week 24
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Ahmedabad, India
GSK Investigational Site
Ahmedabad, India
GSK Investigational Site
Byculla Mumbai, India
GSK Investigational Site
Hyderabad, India
GSK Investigational Site
Hyderabad, India
GSK Investigational Site
Hyderabad, India
GSK Investigational Site
Jaipur, India
GSK Investigational Site
Kanpur, India
GSK Investigational Site
Kolkata, India
GSK Investigational Site
Nagpur, India
GSK Investigational Site
New Delhi, India
GSK Investigational Site
Noida, India
GSK Investigational Site
Pune, India
GSK Investigational Site
Pune, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.